Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Abstract: [Object] To provide the disc brake pad including the friction material having the friction surface with the scorch treatment that can provide sufficient braking effectiveness while preventing the fading phenomenon at the initial stage of the disc brake pad usage. [Means to Resolve] In the disc brake pad including the friction material having the friction surface with the heat history due to the scorch treatment, the friction surface has the mixed areas including the area with the large heat history of the scorch treatment and the area with relatively small heat history of the scorch treatment.

Abstract: [Object] To provide the method of manufacturing the friction material that is capable of uniformly scorching into the deep part of the surface layer of the friction material in a short period of time. [Means to Resolve] In the method of manufacturing the friction material including the scorching step of scorching the surface of the friction material with the laser, the friction material contains 5 to 25% by weight of one or more types of black materials relative to the total amount of the friction material composition, and the L* of the CIE Lab of the surface of the friction material before scorching is 20 to 60.

Abstract: A wire bonding method includes bringing a capillary and a wire inserted through the capillary into pressure contact with a bonding point of a lead placed on an XY stage to bond the wire to the lead, including moving the XY stage in a state in which the capillary is in pressure contact with the lead to move the capillary along a movement locus including a plurality of arc portions.

Abstract: [Object] To provide the underlayer composition for the disc brake pad, which may be applicable to the manufacturing process of softening the rubber by heating even if the uncrosslinked fluororubber in the underlayer composition and the disc brake pad with an excellent brake noise suppression effect. [Means to Resolve] To use the underlayer composition containing 5-15 weight % of the uncrosslinked fluororubber relative to the entire amount of the underlayer composition, 4-8 weight % of the phenol-based resin as the binder relative to the entire amount of the underlayer composition, and 0.3-2 weight % of the hexamethylenetetramine as the curing agent for the phenol-based resin relative to the entire amount of the underlayer composition.

Abstract: A crystal device includes a rectangular shaped substrate, a mounting frame which is along an outer circumferential edge of a lower surface of the substrate on its short-side sides and configures a recessed part, electrode pads on an upper surface of the substrate, connection pads on the lower surface of the substrate in the mounting frame, a crystal element mounted on the electrode pads, a temperature sensing element mounted on the connection pads, and a lid air-tightly sealing the crystal element. The electrode pads and the recessed part do not overlap in a plane perspective view.

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Abstract: Provided is a wire bonding method capable of suppressing the occurrence of wire breakage. One aspect of the present invention provides a wire bonding method for bringing a capillary and a wire 1 inserted through the capillary into pressure contact with a second bonding point 16 of a lead placed on an XY stage to bond the wire to the lead, including moving the XY stage in a state in which the capillary is in pressure contact with the lead to move the capillary along a movement locus including a plurality of arc portions.

Abstract: [Object] To provide the method of manufacturing the friction material that is capable of uniformly scorching into the deep part of the surface layer of the friction material in a short period of time. [Means to Resolve] In the method of manufacturing the friction material including the scorching step of scorching the surface of the friction material with the laser, the friction material contains 5 to 25% by weight of one or more types of black materials relative to the total amount of the friction material composition, and the L* of the CIE Lab of the surface of the friction material before scorching is 20 to 60.

Abstract: A piezoelectric vibration device includes an element mounting member provided with a recessed part, a vibration element held in the recessed part, and a lid closing the recessed part. The element mounting member includes an insulating base body including an inner bottom surface of the recessed part and an inner circumferential surface of the recessed part surrounding the inner bottom surface, a pair of signal terminals which are located on an outer surface of the base body and are electrically connected to the vibration element, a GND terminal which is located on the outer surface of the base body, and a shield film which is superposed on the inner circumferential surface of the recessed part and is electrically connected to the GND terminal.

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.

Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.

Abstract: A crystal device includes a rectangular shaped substrate, a mounting frame which is along an outer circumferential edge of a lower surface of the substrate on its short-side sides and configures a recessed part, electrode pads on an upper surface of the substrate, connection pads on the lower surface of the substrate in the mounting frame, a crystal element mounted on the electrode pads, a temperature sensing element mounted on the connection pads, and a lid air-tightly sealing the crystal element. The electrode pads and the recessed part do not overlap in a plane perspective view.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

Abstract: A piezoelectric vibration device includes an element mounting member provided with a recessed part, a vibration element held in the recessed part, and a lid closing the recessed part. The element mounting member includes an insulating base body including an inner bottom surface of the recessed part and an inner circumferential surface of the recessed part surrounding the inner bottom surface, a pair of signal terminals which are located on an outer surface of the base body and are electrically connected to the vibration element, a GND terminal which is located on the outer surface of the base body, and a shield film which is superposed on the inner circumferential surface of the recessed part and is electrically connected to the GND terminal.

Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.